Less than a tenth of individuals that would benefit from GLP-1 drugs such as Wegovy can access them, caution the World Health Organization as it issues its first advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a chronic disease that can be treated with holistic and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are major hurdles to broad access to the treatments that can help people shift considerable weight, says the body.
Skinny Jab Supply Crisis
Despite the present most optimistic outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation calls on countries and companies to increase access, by strategies including licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is due to expire in several nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and increase satiety so individuals reduce food intake.
Individuals commonly start to lose weight within a few weeks of commencing the regular doses.
Research indicates users may see weight return within a year of discontinuing the medication, as their normal food cravings come back.
To be overweight or obese elevates your likelihood for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
